When to Give Lidocaine 100mg IV
Give lidocaine 100 mg IV as an initial bolus for ventricular fibrillation (VF) or pulseless ventricular tachycardia (VT) during cardiac arrest when the rhythm persists after defibrillation attempts 1.
Primary Indication: Cardiac Arrest with Refractory VF/Pulseless VT
Lidocaine is indicated for VF or pulseless VT that is unresponsive to defibrillation 2. The 100 mg bolus dose is specifically recommended in the cardiac arrest setting 1. This can be repeated after 5-10 minutes if VF/pulseless VT persists 1.
Dosing Algorithm for Cardiac Arrest:
- First dose: 100 mg IV bolus (can also use weight-based 1.0-1.5 mg/kg) 3, 2
- Second dose if needed: 0.5-0.75 mg/kg (approximately 50 mg) after 5-10 minutes 3, 1
- Maximum cumulative dose: 3 mg/kg 3
- Maintenance infusion: 2-4 mg/min if successful cardioversion occurs 1
Secondary Indication: Hemodynamically Stable Monomorphic VT
For stable monomorphic VT without hemodynamic compromise (no angina, pulmonary edema, or hypotension <90 mmHg systolic), lidocaine can be used but is now considered second-line therapy 3.
Important Context on Efficacy:
Lidocaine is less effective than procainamide, sotalol, and amiodarone for terminating VT 3. The 2010 AHA guidelines explicitly state lidocaine should be considered second-line antiarrhythmic therapy for monomorphic VT 3. Amiodarone or procainamide are preferred first-line agents for stable VT 3, 4.
Dosing for Stable VT:
- Initial bolus: 1.0-1.5 mg/kg (75-100 mg) over 1-2 minutes 4
- Supplemental boluses: 0.5-0.75 mg/kg every 5-10 minutes as needed 4
- Maximum total loading: 3 mg/kg 4
- Maintenance: 2-4 mg/min (30-50 mcg/kg/min) 3, 4
When NOT to Give Lidocaine
Contraindications and Cautions:
Do NOT use lidocaine for:
- Prophylactic administration in uncomplicated acute MI without ventricular arrhythmias 5
- Patients with known lidocaine allergy 5
- Irregular or polymorphic wide-complex tachycardia 3
- Supraventricular tachycardia (lidocaine has no effect on SVT) 1
Use with extreme caution and reduced doses in:
- Patients >70 years old (higher risk of toxicity) 5
- Heart failure or cardiogenic shock (reduced clearance) 5
- Hepatic dysfunction (lidocaine is metabolized by liver) 6
- Severe renal dysfunction 5
- Pre-existing neurologic dysfunction 5
Critical Dosing Considerations
Weight-Based Dosing is Essential:
The FDA label and guidelines emphasize dosing based on lean body weight 5, 6. For a 70 kg patient, 100 mg represents approximately 1.4 mg/kg, which is within the recommended 1.0-1.5 mg/kg range.
Patients with Heart Failure:
Recent evidence suggests that in patients with heart failure and ventricular arrhythmias, the optimal initial infusion rate is 1 mg/min (not higher rates up to 4 mg/min) 7. This achieved therapeutic levels in 66% of patients while minimizing toxicity.
Toxicity Monitoring:
Watch for CNS toxicity signs: slurred speech, altered consciousness, perioral numbness, dizziness, confusion, muscle twitching, seizures 3, 5. Also monitor for bradycardia and hypotension 3.
Current Guideline Position
The 2018 AHA Focused Update now includes lidocaine alongside amiodarone in the ACLS algorithm for shock-refractory VF/pVT 2. However, this is a Class IIb recommendation (may be considered), particularly useful for witnessed arrests where time to drug administration is shorter 2.
Key limitation: No antiarrhythmic drug, including lidocaine, has been shown to improve long-term survival or neurological outcomes after cardiac arrest 2. The recommendation is based on modest improvements in short-term outcomes like return of spontaneous circulation (ROSC) and survival to hospital admission in witnessed arrests 2.
Prophylactic Use is NOT Recommended
Historical practice of prophylactic lidocaine in acute MI is no longer recommended (Class III) 5. Meta-analysis showed it may reduce VF by 33% but provides no mortality benefit and may increase deaths from asystole 5. The 1992 North-Norwegian trial found prophylactic lidocaine ineffective in preventing VF in prehospital MI 8.